Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines
J. Clin. Invest. Rachel H. McMahan, et al. 116:2543 doi:10.1172/JCI26936 [Go to this article.]

Figure 4
The AH1-specific T cell response was strongest after priming with the intermediate-binding mimotopes. (A) BALB/c mice with day 4 established tumors were injected with LANAC and the indicated peptides. On day 14, TILs were isolated and stained ex vivo with CD8 antibody and L^d-tet bound to either the AH1 or β-gal peptide. The percentages of tetramer-positive CD8⁺ cells are indicated. (B) Using the methods from A, the mean ± SEM of AH1-specific CD8⁺ TILs was calculated for 4 mice per vaccine. (C) L^d-tet/AH1–positive CD8⁺ T cells from tumors of mice vaccinated with AH1 (filled), mimotope 39 (black line), or mimotope 15 (gray line) peptides were stained ex vivo with CD69, CD44, CD122, and TCRβ antibodies. Staining of activation markers was not performed for the other mimotopes.